The U.S. Food and Drug Administration (FDA) has approved the first generic version of a daily injectable GLP-1 medication for patients aged 10 and older with Type 2 diabetes. The medication, a lower-cost alternative to the brand-name drug Victoza, or liraglutide, aims to improve blood sugar control when used alongside diet and exercise. The approval was granted to Hikma Pharmaceuticals, a British company. The FDA approved the drug as certain GLP-1 medications, including liraglutide, face ongoing shortages. The generic version is expected to expand access for patients managing diabetes, which affects more than 38 million Americans, according to federal health data. Dr. Iilun Murphy, director of the FDA’s Office of Generic Drugs, said the FDA supports the development of generic drugs, such as GLP-1s, by funding research and informing industry through guidance….